Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company also develops Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other GI diseases, as well as nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555
Debt
Debt-to-Equity RatioN/A
Current Ratio27.27
Quick Ratio27.27
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.01 per share
Price / Book5.43
Profitability
EPS (Most Recent Fiscal Year)($3.15)
Net Income$-24,410,000.00
Net MarginsN/A
Return on Equity-21.17%
Return on Assets-17.56%
Miscellaneous
Employees22
Outstanding Shares11,940,000
Market Cap$389.43
Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions
What is Albireo Pharma's stock symbol?
Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."
How were Albireo Pharma's earnings last quarter?
Albireo Pharma Inc (NASDAQ:ALBO) released its quarterly earnings data on Thursday, May, 17th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $3.75 by $3.90. The biopharmaceutical company had revenue of $11.20 million for the quarter, compared to analyst estimates of $55.33 million. View Albireo Pharma's Earnings History.
What price target have analysts set for ALBO?
5 brokerages have issued 1 year price objectives for Albireo Pharma's shares. Their predictions range from $50.00 to $92.00. On average, they anticipate Albireo Pharma's share price to reach $65.25 in the next twelve months. This suggests a possible upside of 100.1% from the stock's current price. View Analyst Ratings for Albireo Pharma.
What is the consensus analysts' recommendation for Albireo Pharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Albireo Pharma stock?
Here are some recent quotes from research analysts about Albireo Pharma stock:
- 1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (3/30/2018)
- 2. Needham & Company LLC analysts commented, "Albireo mgmt hosted a 4Q17 conference call today to provide a corporate update. Company remains on track for initiation of Phase 3 testing of IBAT inhibitor A4250 in Progressive Familiar Intrahepatic Cholestasis (PFIC) in the near future. As a reminder, Albireo presented encouraging data from a Phase 2 trial in rare pediatric cholestatic liver diseases, including PFIC, in 2017. Mgmt guided for Phase 3 top-line results by YE19, w/ regulatory submissions shortly thereafter. Albireo also plans to evaluate elobixibat in Non-Alcoholic Steatohepatitis (NASH), although not until early 2019. Evaluation of A4250 in other rare pediatric cholestatic liver diseases and testing of A3384 in Bile Acid Malabsorption is still planned, but deprioritized in order to focus on A4250 in PFIC. We believe stock is undervalued and reiterate BUY." (3/15/2018)
- 3. Wedbush analysts commented, "Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders." (1/3/2018)
- 4. Cowen Inc analysts commented, "Albireo reported 3Q earnings today and provided a brief summary of recent progress." (11/17/2017)
Who are some of Albireo Pharma's key competitors?
Some companies that are related to Albireo Pharma include IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), Corcept Therapeutics (CORT), Innoviva (INVA), Biohaven Pharmaceutical (BHVN), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH), Arrowhead Pharmaceuticals (ARWR), Deciphera Pharmaceuticals (DCPH), Amneal Pharmaceuticals (AMRX), ImmunoGen (IMGN), Lexicon Pharmaceuticals (LXRX), Impax Laboratories (IPXL) and Myovant Sciences (MYOV).
Who are Albireo Pharma's key executives?
Albireo Pharma's management team includes the folowing people:
- Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 55)
- Dr. Paresh N. Soni, Chief Medical Officer (Age 58)
- Ms. Martha J. Carter, Chief Regulatory Officer (Age 66)
- Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
- Mr. Thomas A. Shea, CFO, Treasurer & Sec. (Age 58)
Has Albireo Pharma been receiving favorable news coverage?
News headlines about ALBO stock have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Albireo Pharma earned a news sentiment score of 0.07 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Albireo Pharma's major shareholders?
Albireo Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Chicago Capital LLC (1.13%) and Hartwell J M Limited Partnership (0.11%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Life Sciences Maste Perceptive, Phase4 Partners Ltd and Plc Astrazeneca. View Institutional Ownership Trends for Albireo Pharma.
Which major investors are buying Albireo Pharma stock?
How do I buy shares of Albireo Pharma?
Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albireo Pharma's stock price today?
One share of ALBO stock can currently be purchased for approximately $32.61.
How big of a company is Albireo Pharma?
Albireo Pharma has a market capitalization of $389.43 million. The biopharmaceutical company earns $-24,410,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Albireo Pharma employs 22 workers across the globe.
How can I contact Albireo Pharma?
Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]
MarketBeat Community Rating for Albireo Pharma (NASDAQ ALBO)
MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
